It is concluded that precision medicine in RA will require integrated biomarker panels combining clinical, pharmacological, molecular, and synovial tissue data, and the development of scalable, externally validated, and clinically interpretable models capable of assigning synovial endotypes and supporting mechanism-based therapeutic selection.
N. A. Batashkov, E. Gerasimova, D. Gerasimova et al.· Frontiers in Immunology· 0 citations
A male infant with a severe FINCA-like phenotype is reported, including early-onset hemolytic anemia, pulmonary involvement, neurodevelopmental impairment, growth failure, recurrent infections, and fatal progression at 8.5 months.
A. Rozhkova, Anton Esibov, A. Borkovskaia et al.· International Journal of Mol...· 0 citations